Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,321
datasets available to search
ShareScore release 0.9.0
Dataset results
1,321 results for “HIV-1”
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
ClinicalTrials.gov study NCT03787095. IPD Sharing: YES. Countries: 1. Publications: 2.
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
ClinicalTrials.gov study NCT01704781. IPD Sharing: NO. Countries: 1. Publications: 4.
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
ClinicalTrials.gov study NCT03739996. IPD Sharing: YES. Countries: 2. Publications: 1.
Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
ClinicalTrials.gov study NCT03048422. IPD Sharing: YES. Countries: 9. Publications: 5.
Optimized SMRT-UMI protocol produces highly accurate sequence datasets from diverse populations – application to HIV-1 quasispecies
Open the record for dataset details and reuse information.
Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: an open-label randomized controlled trial in Lesotho
<p>These are pseudo-anonymised data from the SESOTHO randomised trial: "Switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL – a multicenter, parallel-group, open-label, randomized clinical study in rural Lesotho". There are two datasets, one containing baseline data (one row per participant) and one containing longitudinal viral load data (one row per participant per visit). The data dictionary explains the data available in each dataset. Between August 2017 and August 2019, 80 eligible and consenting participants were enrolled from eight health facilities in four districts of Lesotho, and followed up for nine months. The protocol was published, DOI: 10.1186/s12879-018-2979-y</p>
Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection
<p><strong>Background:</strong> Haplotype-specific alternative splicing of the endoplasmic reticulum (ER) aminopeptidase type 2 (ERAP2) gene results in either full-length (FL, haplotype A) or alternatively spliced (AS, haplotype B) mRNA. HapA/HapA homozygous (HomoA) subjects show a reduced susceptibility to HIV-1 infection, probably secondary to the modulation of the antigen processing/presenting machinery. ERAP1 was recently shown to be secreted from the plasma membrane in response to activation; we investigated whether ERAP2 can be released as well and if the secreted form of this enzyme retains its antiviral function.</p> <p><strong>Methods:</strong> Human monocyte derived macrophages (MDMs) were differentiated from peripheral blood mononuclear cells (PBMCs) isolated from 6 HomoA healthy controls and stimulated with IFNγ and LPS. ERAP2-FL secretion was evaluated by mass spectrometry. PBMCs (14 HomoA and 16 HomoB) and CD8-depleted PBMCs (CD8<sup>−</sup>PBMCs) (4 HomoA and 4 HomoB) were <em>in vitro</em> HIV-infected in the absence/presence of recombinant human ERAP2-FL (rhERAP2) protein; p24 viral antigen quantification was used to assess viral replication. IFNγ and CD69 mRNA expression, as well as the percentage of perforin-producing CD8+ T Lymphocytes, were analyzed 3 and 7-days post <em>in vitro</em> HIV-1-infection, respectively. The effect of rhERAP2 addition in cell cultures on T cell apoptosis, proliferation, activation, and maturation was evaluated as well on 24 h-stimulated PBMCs.</p> <p><strong>Results:</strong> ERAP2 can be secreted from human MDMs in response to IFNγ/LPS stimulation. Notably, the addition of rhERAP2 to PBMC and CD8<sup>−</sup>PBMC cultures resulted in the reduction of viral replication, though these differences were statistically significant only in PBMCs (<em>p</em> < 0.05 in both HomoA and HomoB). This protective effect was associated with an increase in IFNγ and CD69 mRNA expression and in the percentage of perforin-expressing CD107<sup>+</sup>CD8<sup>+</sup> cells. RhERAP2 addition also resulted in an increase in CD8<sup>+</sup> activated lymphocyte (CD25<sup>+</sup>HLA<sup>−</sup>DRII<sup>+</sup>) and Effector Memory/Terminally differentiated CD8<sup>+</sup> T cells ratio.</p> <p><strong>Conclusions:</strong> This is the first report providing evidence for the release of ERAP2 in the secretome of immunocompetent cells. Data herein also indicate that exogenous ERAP2-FL exerts its protective function against HIV-1 infection, even in HomoB subjects who do not genetically produce it. Presumably, this defensive extracellular feature is only partially dependent on immune system modulation.</p>
Data from: 1970s and 'Patient 0' HIV-1 genomes illuminate early HIV/AIDS history in North America
The emergence of HIV-1 group M subtype B in North American men who have sex with men was a key turning point in the HIV/AIDS pandemic. Phylogenetic studies have suggested cryptic subtype B circulation in the United States (US) throughout the 1970s1, 2 and an even older presence in the Caribbean2. However, these temporal and geographical inferences, based upon partial HIV-1 genomes that postdate the recognition of AIDS in 1981, remain contentious3, 4 and the earliest movements of the virus within the US are unknown. We serologically screened >2,000 1970s serum samples and developed a highly sensitive approach for recovering viral RNA from degraded archival samples. Here, we report eight coding-complete genomes from US serum samples from 1978–1979—eight of the nine oldest HIV-1 group M genomes to date. This early, full-genome 'snapshot' reveals that the US HIV-1 epidemic exhibited extensive genetic diversity in the 1970s but also provides strong evidence for its emergence from a pre-existing Caribbean epidemic. Bayesian phylogenetic analyses estimate the jump to the US at around 1970 and place the ancestral US virus in New York City with 0.99 posterior probability support, strongly suggesting this was the crucial hub of early US HIV/AIDS diversification. Logistic growth coalescent models reveal epidemic doubling times of 0.86 and 1.12 years for the US and Caribbean, respectively, suggesting rapid early expansion in each location3. Comparisons with more recent data reveal many of these insights to be unattainable without archival, full-genome sequences. We also recovered the HIV-1 genome from the individual known as 'Patient 0' (ref. 5) and found neither biological nor historical evidence that he was the primary case in the US or for subtype B as a whole. We discuss the genesis and persistence of this belief in the light of these evolutionary insights.
High frequency of X4/DM-tropic viruses in PBMC samples from HIV-1 recently infected blood donors by massively parallel sequencing: the REDS II Study
<p>Here is a sub-library of the <em>env</em> V3 massively parallel sequencing proviral data generated (by Illumina MiSeq platform) during the early phase of HIV-1 infection in a group of first-time blood donors. Only paired-end reads that encompass the complete V3 region from each dataset were extracted, uploaded and considered for the analysis to avoid artificial generation of <em>in silico</em> chimeras through assembly and to evade inflating the diversity estimates of the V3 region</p>
Dataset STI screening German HIV-1 seroconverter cohort
<p>The Stata file contains the raw data of a project in the scope of the German HIV-1 seroconverter cohort, run by the Robert Koch Institute, Berlin, Germany. The data covers anonymous sociodemographic and clinical information of the patients as well as results of a serologocal screening on coinfection with hepatitis B, hepatitis C and syphilis.</p>
A rapid and versatile tool for HIV-1 Drug Resistance Genotyping by Deep Sequencing: supporting dataset
<p>See file `viral_mixes.md` and [manuscript](http://www.sciencedirect.com/science/article/pii/S0166093416301987).</p> <div class="grammarly-disable-indicator"> </div> <div class="grammarly-disable-indicator"> </div>
Supplementary Material: HIV-1-Induced Small T Cell Syncytia Can Transfer Virus Particles to Target Cells through Transient Contacts
<p>Videos supplementary to <em>Viruses</em> <strong>2015</strong>, <em>7</em>(12), 6590-6603; doi:10.3390/v7122959</p> <p><strong>Captions:</strong></p> <p><strong>Movie S1.</strong> <strong>HIV-1-infected cells in the lymph node of humanized mice.</strong></p> <p>Humanized BLT mice were injected in the footpad with HIV-nGFP, where GFP is highly enriched in cellular nuclei, and the draining popliteal lymph node prepared for MP-IVM at day 2. Representative infected cells (GFP+; green) that display one, two or three discernible nuclei are shown (<strong>top</strong>). In the bottom panels, green fluorescence signals above 80% of the intensity maximum were used to define cell nuclei, which are shown in white. The syncytium with two discernible nuclei remains elongated throughout the recording, while the syncytium with three discernible nuclei switches between coordinated and uncoordinated motility. Each individual frame is a maximum intensity projection of 11 <em>z</em>-stacks spaced 4 μm apart (for a total volume of 40 μm). Time is shown in minutes and seconds. Scale bar = 20 μm. See also Figure 1A.</p> <p><strong>Movie S2.</strong> <strong>Syncytia in the lymph node contact uninfected T cells without undergoing cell-cell fusion</strong>.</p> <p><em>In vitro</em>-generated central memory CD4+ T cells, either infected with HIV-GFP (GFP+; green) or uninfected (labeled with CellTracker Orange; red), were adoptively transferred by footpad injection into BLT mice pretreated with antiretroviral drugs (100 mg/kg FTC, 150 mg/kg TDF). After 12 h, the draining popliteal lymph node was prepared for MP-IVM. Two representative movies of T cell migration prior to (yellow circle) and during<br /> (blue circle) transient interactions with syncytia are shown, demonstrating cellular interactions without fusion. Each individual frame is a maximum intensity projection of 11 <em>z</em>-stacks spaced 4 μm apart (for a total volume of 40 μm). Time is shown in minutes and seconds. Scale bar = 40 μm. See also Figure 1F,G.</p> <p><strong>Movie S3.</strong> <strong>CD4</strong><strong>+ T cells in 3D culture form small syncytia with elongated morphology</strong>.</p> <p>Primary human CD4+ T cells isolated from a healthy donor were infected with VSV-G-pseudotyped NL4-3<sup>Gag-iGFP</sup> virus. The next day, cells were embedded in a 3D collagen gel as described in the Experimental Section, and 12 h later imaged live at 37 °C using a 20× objective on a DeltaVision widefield microscope. Six 3 µm-spaced Z-slices were taken every 20 s, and were subsequently projected into one image. The syncytium seen here in green has two nuclei located at opposite ends, and a central bulged region with high amounts of viral Gag. The diffuse fluorescence is a result of this syncytium being located at a higher part of the gel, where the limitations of widefield imaging become more prominent. See also Figure 2A.</p> <p><strong>Movie S4.</strong> <strong>Small CEM-SS syncytia in 3D culture can dynamically change their morphology</strong>.</p> <p>CEM-SS cells were infected with VSV-G-pseudotyped NL4-3<sup>Gag-iGFP</sup> virus. The next day, cells were embedded in a 3D Matrigel gel as described in the Experimental Section, and 24 h later imaged live at 37 °C using a<br /> 40× objective on a DeltaVision widefield microscope. Seven 2 μm-spaced Z-slices were taken every 5 min, and were subsequently projected into one image. A syncytium with two nuclei (dark areas within the cell in the GFP channel) begins with two lobes, which merge into a coordinated round morphology as the cell begins to migrate through the gel and leaves the plane of focus. See also Figure 2B.</p> <p><strong>Movie S5.</strong> <strong>CD4</strong><strong>+ T cells in 3D culture exhibit </strong><strong><em>in vivo</em>-like migratory behavior</strong>.</p> <p>Primary human CD4<sup>+</sup> T cells were infected, embedded in collagen, and imaged as in Movie S3 (though with a<br /> 10 s time lapse). The uninucleated infected cell migrating across the field moves by 108 μm over 560 s, for a mean velocity of 11.58 μm/min. Such fast directed amoeboid motility is not typically observed in classical 2D culture and requires the presence of a 3D ECM. See also Figure 2C.</p> <p><strong>Movie S6.</strong> <strong>Uninucleated infected cells and syncytia can transfer virus to target cells without fusion.</strong></p> <p>CEM-SS cells were infected, embedded in Matrigel, and imaged as in Movie S4. Virus transfer from a uninucleated infected cell (top) and a syncytium (bottom left) to a number of target cells (denoted by T) can be seen here.<br /> The uninucleated infected cell transfers virus to target cells T1–T5, and the syncytium transfers virus to target cells T6–T7. Images shown represent brightfield in gray (bottom right), or Gag-iGFP in green, shown either with normal scaling (bottom left, and merged with brightfield at top right), or with a 0.6 gamma correction applied and enhanced scaling to better show appearance of Gag-iGFP puncta on target cells (top left). Scale bar = 30 μm. A yellow arrow indicates the moment where the uninucleated infected cell begins transferring virus to target cells T1–T3, and all of the other transfer events in this field are happening at roughly the same time. At this time, Gag-iGFP puncta appear to distribute between cells T1–T3 in a progressive fashion, beginning from the point of contact with the infected cell (see also Figure 3A, middle panel). Cells T4 and T5 also receive virus particles from this infected cell, and T4 can be seen migrating away at the end. Also note a trail of released virus left behind by the uninucleated infected cell as it migrates from left to right from 08:00:00 to 09:10:00 (see also Movies S7 and S9, Figure 4 for similar events in syncytia). The syncytium’s targets, T6 and T7, are already in intimate contact with it at the start of the movie, and are obscured by lobes of the syncytium. At the 10:45:00 mark, cell T6 breaks free from the syncytium, now harboring a large amount of virus particles on its surface, as the syncytium slowly migrates away, and cell T7 also appears to harbor virus particles on its surface by the final time point.</p> <p><strong>Movie S7.</strong> <strong>A virus transfer event between a syncytium and two uninfected target cells.</strong></p> <p>CEM-SS cells were infected, embedded in Matrigel, and imaged as in Movies S4 and S6. The syncytium shown here initially has two nuclei, but soon fuses with an uninfected cell and now has three clearly visible nuclei. It remains stationary for several hours, before beginning to migrate towards a pair of uninfected target cells (top). Very soon after contact, virus particles can be seen covering the surface of both cells, one of which eventually migrates away. See also Figure 3A (left panel). Note also another instance of a dense accumulation of cell-free virus particles in what appears to be a pocket within the hydrogel that the syncytium moves one of its lobes out of, revealing the deposited free virus, before it moves back into the pocket. See also Figure 4A.</p> <p><strong>Movie S8.</strong> <strong>Cell-to-cell transfer of virus can take place while cells are migrating.</strong></p> <p>CEM-SS cells were infected, later mixed with CMAC-labeled uninfected CEM-SS cells (shown in blue), embedded in collagen, and imaged as above. A syncytium with two nuclei (one of which bears CMAC signal, indicating that it formed recently and not before the infected culture was mixed with the labeled uninfected cells) migrates across the field. Its trailing edge contacts an uninfected CMAC-labeled cell, which is then dragged along with it, and finally dropped in the corner of the field. The target cell now bears virus particles on its surface, and is no longer in contact with the syncytium, which has moved into a different focal plane and stopped migrating (not shown). The image was refocused at the 10:30:00 mark to better show the target cell and the virus particles on its surface. Note that this movie also shows an instance of newly synthesized Gag-iGFP appearing in a previously uninfected cell (not the target cell contacted by the syncytium). This non-CMAC labeled uninfected cell appears in the bottom left of the field at 07:20:00 and exhibits steadily increasing diffuse intracellular signal, as documented in Figure 3A (right) and Figure 3B,C (green traces).</p> <p><strong>Movie S9.</strong> <strong>Migrating infected cells can deposit a trail of released virus particles</strong>.</p> <p>CEM-SS cells were infected, embedded in Matrigel, and imaged as in Movies S4, S6, and S7. A syncytium with 3 nuclei switches into a coordinated morphology and begins migrating across the field. Released virus particles can be seen in its wake (also shown enlarged and with increased brightness as an inset). Shortly after the end of the movie, the cell-free virus accumulation appeared to dissipate (not shown), but it could not be determined whether this was because of photobleaching or if they had in fact diffused away. See also Figure 4B.</p>
Ultra-deep sequencing of HIV-1 near full-length and partial proviral genomes reveals high genetic diversity among Brazilian blood donors
<p>Here, we aimed to gain a comprehensive picture of the HIV-1 diversity in the northeast and southeast part of Brazil. To this end, a high-throughput sequencing-by-synthesis protocol and instrument were used to characterize the near full length (NFLG) and partial HIV-1 proviral genome in 259 HIV-1 infected blood donors at four major blood centers in Brazil: Pro-Sangue foundation (São Paulo state (SP), n 51), Hemominas foundation (Minas Gerais state (MG), n 41), Hemope foundation (Recife state (PE), n 96) and Hemorio blood bank (Rio de Janeiro (RJ), n 70).</p>
Massively parallel sequencing data of the HIV-1 pol region generated from the plasma of therapy-naïve chronically infected Brazilian blood donors
<p>The submitted massively parallel sequencing (MPS) data were partial data from the pol region of HIV-1 plasma viruses. Samples were obtained from 18 therapy-naive HIV-1 Brazilian blood donors with longstanding infection. Illumina ultra-deep sequencing technology (MiSeq platform) was used to generate the sequences. </p>
Improved production of HIV-1 subtype C protease from transgenic E coli
<p>The data set belongs to study carried out by Uraisha Ramlucken at Department of Biochemistry, University of KwaZulu-Natal, Durban, South Africa. This study was made possible through financial support from the National Research Foundation.</p>
Datasets for: The HIV-1 viral protease is activated during assembly and budding prior to particle release
<p>HIV-1 encodes a viral protease that is essential for the maturation of infectious viral particles. While protease inhibitors are effective antiretroviral agents, recent studies have shown that prematurely activating – rather than inhibiting – protease function leads to the pyroptotic death of infected cells, with exciting implications for efforts to eradicate viral reservoirs. Despite 40 years of research into the kinetics of protease activation, it remains unclear exactly when protease becomes activated. Recent reports have estimated that protease activation occurs minutes to hours after viral release, suggesting that premature protease activation may be challenging to induce efficiently. Here, combining a powerful FRET-based assay to monitor viral protease activity with sensitive techniques including nanoscale flow cytometry and instant structured illumination microscopy, we demonstrate that the viral protease is activated within cells prior to the release of free virions. Using genetic mutants that lock protease into a 'precursor' conformation, we further show that both the precursor and mature protease have rapid activation kinetics and that the activity of the precursor protease is sufficient for viral fusion with target cells. Our finding that HIV-1 protease is activated within producer cells prior to release of free virions helps resolve a long-standing question of when protease is activated and suggests that only a modest acceleration of protease activation kinetics may be required to induce potent and specific elimination of HIV-infected cells.</p>
Consensus nucleotide sequences for env and gag for paper: Insights to HIV-1 coreceptor usage by estimating HLA adaptation with Bayesian generalized linear mixed models
<p>This is the consensus sequence repository to the manuscript "Insights to HIV-1 coreceptor usage by estimating HLA adaptation with Bayesian generalized linear mixed models".<br> It contains the 10% consensus nucleotide sequences of the env and gag (only p24) protein of HIV-1 used for the training and leftout data set. The NGS sequences are available under BioProject ID PRJNA810303 and the corresponding BioSample Accession IDs are SAMN26241863:26242168 and SAMN28728524:SAMN28728529</p> <ul> <li>env_leftout.fasta <ul> <li>A fasta file that contains the consensus nucleotide sequences for the env protein for the leftout data set</li> </ul> </li> <li>env_nt_274.fasta <ul> <li>A fasta file that contains the consensus nucleotide sequences for the env protein for the training data set</li> </ul> </li> <li>gag_leftout.fasta <ul> <li>A fasta file that contains the consensus nucleotide sequences for the gag protein for the leftout data set</li> </ul> </li> <li>gag_nt_274.fasta <ul> <li>A fasta file that contains the consensus nucleotide sequences for the gag protein for the training data set</li> </ul> </li> </ul>
Supplementary Data and Figures for "Myomedin replicas of gp120 V3 loop glycan epitopes of PGT121 and PGT126 antibodies as non-cognate antigens for HIV-1 broadly neutralizing antibodies"
<p>Supplementary pymol sessions for "Myomedin replicas of gp120 V3 loop glycan epitopes of PGT121 and PGT126 antibodies as non-cognate antigens for HIV-1 broadly neutralizing antibodies". Pymol sessions contain the source data for Figure 3, panels A-K.</p>
HIV-1 capsid assembly
<p>This dataset contains all information to run HIV-1 capsid assembly simulations in the presence of IP6.</p>
3D-coordinates of the complex formed by TRN-1 and CA hexamer from HIV-1 and MD simulation of H27 with CA hexamer
<p>The complex formed by HIV-1 CA hexamer (based on 3H4E) and Transportin-1 (TRN-1, based on 4FQ3) was first obtained by rigid docking and optimized by MD simulations and finally energy minimized using NAMD program and Charmm36m force field. This complex was used for the in silico screening study for discovering new antiviral drugs.</p> <p>The 3D coordinates (PDB file) of CA hexamer in presence of H27</p> <p>The corresponding trajectory of MD simulation (500 ns) of H27 with CA hexamer in order to find preferential binding sites (trajectory reduced or strided for reducing the size of the file</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.